Lupus associated hepatitis in active lupus nephritis patient: A case report

Sham Sunder, Satyanand Sathi, Himanshu Mahapatra, Rajesh J, Anurag Gupta, Prabhu K

ABSTRACT

Introduction: Systemic lupus erythematosus and autoimmune hepatitis (AIH) both are autoimmune disease causing inflammation of the liver. It is important to differentiate lupus hepatitis from AIH for diagnosis, treatment and prognosis of the disease.

Case Report: Herein, we report a case of a 17-year-old female with a two-year history of multiple joint pain, six-month history of swelling, rash, mouth ulcers and a 15-day history of jaundice. An investigation revealed positive antinuclear antibody, positive anti-DsDNA, low serum C3, C4, very high serum bilirubin, high SGOT/SGPT and nephrotic range proteinuria. Antibody tests for autoimmune hepatitis were negative. Renal biopsy showed focal proliferative lupus nephritis. Liver biopsy was suggestive of lupus-hepatitis. Jaundice responded to steroid therapy dramatically.

Conclusion: Lupus associated hepatic disease must be differentiated from hepatitis caused by drugs, toxins, viral and other autoimmune diseases. Liver histology may be necessary to confirm a diagnosis.
Lupus associated hepatitis in active lupus nephritis patient: A case report

Sham Sunder, Satyanand Sathi, Himanshu Mahapatra, Rajesh J, Anurag Gupta, Prabhu K

ABSTRACT

Introduction: Systemic lupus erythematosus and autoimmune hepatitis (AIH) both are autoimmune disease causing inflammation of the liver. It is important to differentiate lupus hepatitis from AIH for diagnosis, treatment and prognosis of the disease. Case Report: Herein, we report a case of a 17-year-old female with a two-year history of multiple joint pain, six-month history of swelling, rash, mouth ulcers and a 15-day history of jaundice. An investigation revealed positive antinuclear antibody, positive anti-DsDNA, low serum C3, C4, very high serum bilirubin, high SGOT/SGPT and nephrotic range proteinuria. Antibody tests for autoimmune hepatitis were negative. Renal biopsy showed focal proliferative lupus nephritis. Liver biopsy was suggestive of lupus-hepatitis. Jaundice responded to steroid therapy dramatically. Conclusion: Lupus associated hepatic disease must be differentiated from hepatitis caused by drugs, toxins, viral and other autoimmune diseases. Liver histology may be necessary to confirm a diagnosis.

INTRODUCTION

Systemic lupus erythematosus (SLE) and autoimmune hepatitis (AIH) both are autoimmune disease causing inflammation of the liver. Prior treatment with potentially hepatotoxic drugs or viral hepatitis is usually responsible for the main cause of liver disease in SLE patients. If we exclude all the possible causes of liver disease in a patient of active SLE, primary liver disease may have autoimmune association or may be presentation of active SLE itself. It is necessary to know whether the autoimmune hepatitis and lupus hepatitis are the spectrum of same disease or both are different entities. In this case report, we present lupus associated hepatitis in active lupus nephritis patient.

CASE REPORT

A 17-year-old unmarried female presented with a two-year history of multiple joint pain, six-month history of on and off swelling of whole body, mouth ulcers and characteristic butterfly rash over face and a 15-day history of jaundice. She had been treated on and off with tramadol hydrochloride for joint pain since last six months. No other new medications were reported. She denied any sick contacts, recent travels, or new diet. Her laboratory profile is given in Table 1. Wilson’s disease...
was excluded because of normal serum ceruloplasmin, normal 24-hour urinary copper levels and negative Kayser Fleischer ring on slit lamp microscopy. Serum immunoglobulin G and M levels were increased 3608 and 152 mg/dL, respectively. The patient showed 6 out of 11 American College of Rheumatology (ACR) criteria for SLE which classified her as definite SLE [1]. Renal biopsy revealed class IIIA (focal proliferative) kidney disease

| Table 1: Laboratory profile of the patient. |
|-------------------------------------------|
| Hemoglobin | 7.8 g/dL |
| TLC | 9700/mm³ |
| Platelet count | 2.3x10⁹/mm³ |
| Serum creatinine | 1.5 mg/dL |
| Blood urea | 64 mg/dL |
| Serum albumin | 1.7g/dL |
| AST (SGOT) and ALT (SGPT) | 830 and 698 U/L |
| Serum bilirubin (Total / Direct / Indirect) | 11.21 / 7.45 / 3.76 mg/dL |
| Gamma-glutamyltranspeptidase | 727 U/L (increased) |
| alkaline phosphatase | 505 U/L (increased) |
| ESR | 115 mm |
| Serum CRP | 54 mg/L |
| Serum RA factor | Negative |
| ASO/anti U1 RNP/Anti Jo1 antibody | Negative |
| Antinuclear antibody | Positive |
| Anti-DsDNA | Positive |
| Serum C3 and C4 | 41.1 mg/dL (low) and 4.5 mg/dL (low) |
| Anti-ribosomal P antibody | Positive |
| Serum HIV, HBsAg, antiHCV | Non reactive |
| Hepatitis C virus RNA (by PCR) | Negative |
| IgM anti HAV, Ig M antiHEV | Negative |
| Cytomegalovirus DNA (by PCR) | Negative |
| Epstein-Barr Virus DNA (by PCR) | Negative |
| Antibodies against smooth muscle (SMA) and liver/kidney microsomes (LKM) | |
| Urine routine & microscopy | Protein: 3+, RBCs: 10-15/hpf, WBCs: 2-3/hpf |
| 24-hour urine protein | 6.3 g/day |

Figure 1: Kidney biopsy specimen showing a glomerulus with focal endocapillary proliferation and mesangial expansion (H&E stain, x400).

Figure 2: Capillary and mesangial deposits of IgG in a glomerulus, (Immunofluorescence, x400).

Figure 3: Liver biopsy specimen showing mild chronic hepatitis with predominantly lobular inflammation, with mild chronic inflammatory infiltrate in portal tracts and mild cholestasis with maintained lobular architecture.
according to the International society of nephrology and renal pathology society 2004 classification. Renal biopsy, on light microscopy (Figure 1) showed 6/14 (42.8%) glomeruli with segmental increase in endocapillary cellularity with mesangial expansion and mild neutrophilic infiltration, focal tubular atrophy and necrosis, mild chronic inflammatory infiltrate in interstitium, focal fibrosis and unremarkable vessels. Immunofluorescence showed full house pattern (deposition of IgG, C3, IgA, IgM, C1q and fibrinogen) of immunoglobulin deposition both in mesangium and capillary walls (Figure 2). Liver biopsy showed maintained lobular architecture with mild chronic inflammatory infiltrate in portal tracts with predominantly lobular inflammation and mild cholestasis (Figure 3). Patient was diagnosed to be having lupus nephritis class IIIA with nephrotic syndrome with lupus hepatitis. In the view of class IIIA lupus nephritis with lupus hepatitis, methyl prednisolone 500 mg/day for three days was given followed by 30 mg/day oral prednisolone. Liver function tests (serum bilirubin and SGOT/SGPT) normalized within two weeks. After two weeks, she was managed on the line of lupus nephritis according to Euro-Lupus regimen [2]; cyclophosphamide was given 500 mg intravenously every two weeks for six doses as induction therapy and azathioprine 2.0 mg/kg/day was used as maintenance therapy after two weeks of last cyclophosphamide injection. After six months her serum creatinine was 0.9 mg/dL, 24-hour urine protein was 160 mg/day and liver enzyme levels were within normal limit. After one year follow-up, her serum creatinine was 0.8 mg/dL, 24-hour urine protein was 86 mg/day and liver enzyme levels were within normal limit.

DISCUSSION

One to four percent patients of SLE have jaundice, and it is usually secondary to hemolysis, hepatitis or pancreatitis [3]. Ten to thirty-one percent patients of SLE have hepatomegaly [3]. Elevated liver enzyme levels greater than three times normal are rare in case of active lupus [3]. Infections, salicylates or NSAIDS are responsible for most of the cases [3]. In this case, the patient had active lupus nephritis, hepatomegaly, markedly elevated serum bilirubin and liver enzymes. The incidence of SLE associated hepatitis is difficult to ascertain. Piga et al. reported 5.8% incidence of lupus hepatitis in their study of 242 patients of SLE during a mean follow-up of 72.2 months [4]. Efe et al. reported 4.7% incidence of autoimmune liver disease in SLE patients [5]. Literature shows that anti-ribosomal P-proteins are strongly associated with “lupus hepatitis”, while these antibodies are found in only 10% of patients with SLE without liver disease [6]. This test was found to be positive in our case patient. No drug, alcohol, or other cause is found in approximately one-third of patients with abnormal liver tests in SLE [3]. The biopsy picture of lupus hepatitis shows predominantly lobular inflammation with maintained lobular architecture and mild chronic infiltrate in portal tracts [3]. There is paucity of lymphoid infiltrates and absence of plasma cells in liver biopsy of lupus hepatitis [7]. Liver biopsy of our case patient showed features suggestive of lupus hepatitis. There are three subclasses of AIH in literature. Type 1 AIH is the most common type worldwide (80% cases) and is associated with ANA and/or smooth muscle antibodies (SMA) [8]. Anti-liver/kidney microsomal 1 (Anti-LKM1) antibodies are positive in Type 2 AIH [8]. Type 3 is the least common type of the disease. Anti-soluble liver/liver pancreas antigen (anti-SLA/LP) is present in serum of the patients of Type 3 AIH [8]. The criteria for the diagnosis of AIH in adult patients have been given by the International Autoimmune Hepatitis Group (IAIHG) [9]. Both laboratory and liver histology features are required for the diagnosis and conditions that resemble AIH should be excluded [7] (Table 2). Atsumi et al. reported two cases of severe hepatic involvement without inflammatory changes in systemic lupus erythematosus and found that corticosteroid therapy is effective in lupus hepatitis [10].

Table 2: Differentiating features of Lupus associated hepatitis and autoimmune hepatitis in SLE [4–10].

|                        | Lupus-associated hepatitis | Autoimmune hepatitis |
|------------------------|----------------------------|----------------------|
| Incidence              | 5.8%                       | 4.7%                 |
| ANA+                   | Most of the patients       | 80% Type I AIH       |
| Complement C3, C4      | low in active disease      | Usually normal       |
| Smooth muscle antibody (SMA) | May be positive          | Usually positive in Type I AIH |
| Anti-liver/kidney microsomal 1 antibodies | Negative               | Positive in Type 2 AIH |
| Anti-soluble liver/liver pancreas antigen | Negative               | Positive in Type 3 AIH |
| Anti-ribosomal P antibody | Positive               | Negative              |
| Histology              | Lobular, rarely-periportal, paucity of lymphocytes mild chronic inflammation | Periportal, piecemeal necrosis, plenty of lymphocytes, plasma cell infiltration, interface hepatitis |
| Response to steroids   | Positive response          | Positive response     |
| Progression            | Histopathologically benign | May progress to cirrhosis |
CONCLUSION

Lupus associated hepatic disease must be differentiated from hepatitis caused by drugs, toxins, viral and other autoimmune diseases. Liver histology may be necessary to confirm a diagnosis of lupus hepatitis or autoimmune hepatitis if liver enzymes are increased in the scenario of active systemic lupus erythematosus.

**********

Author Contributions
Sham Sunder – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Satyanand Sathi – Substantial contributions to conception and design, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Himanshu Mahapatra – Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
Rajesh J – Substantial contributions to conception and design, Drafting the article, Final approval of the version to be published
Anurag Gupta – Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
Prabhu K – Substantial contributions to conception and design, Drafting the article, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2014 Sham Sunder et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES

1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40(9):1725.
2. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46(8):2121–31.
3. Dubois’ Lupus erythematosus: Gastrointestinal and hepatic manifestation of systemic lupus erythematosus. 7th edition, Philadelphia, USA; Lipincott Williams & Wilkins 2007. p. 841.
4. Piga M, Vacca A, Porru G, Cauli A, Mathieu A. Liver involvement in systemic lupus erythematosus: Incidence, clinical course and outcome of lupus hepatitis. Clin Exp Rheumatol 2010;28(4):504–10.
5. Efe C, Purnak T, Ozaslan E, et al. Autoimmune liver disease in patients with systemic lupus erythematosus: A retrospective analysis of 147 cases. Scand J Gastroenterol 2011;46(6):732–7.
6. Hulsey M, Goldstein R, Scully L, Surbeck W, Reichlin M. Anti-ribosomal P antibodies in systemic lupus erythematosus: A case-control study correlating hepatic and renal disease. Clin Immunol Immunopathol 1995;74(3):252–6.
7. Wallace DJ. Gastrointestinal manifestations and related liver and biliary disorders In. Dubois Lupus Erythematosus. Wallace DJHB (ed). Philadelphia, Lea and Febiger 1993, pp 410–7.
8. Kenneth Michael Pollard; Autoantibodies and Autoimmunity: Molecular Mechanisms in Health and Disease. USA; Wiley-VCH 2006;13.2.p. 292.
9. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929–38.
10. Atsumi T, Sagawa A, Jodo S, et al. Severe hepatic involvement without inflammatory changes in systemic lupus erythematosus: Report of two cases and review of the literature. Lupus 1995;4(3):225–8.
Edorium Journals: An introduction

Edorium Journals Team

**About Edorium Journals**
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

**Invitation for article submission**
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

**But why should you publish with Edorium Journals?**
In less than 10 words - we give you what no one does.

**Vision of being the best**
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

**Exceptional services**
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

**Editorial Review**
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

**Peer Review**
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

**Early View version**
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

**Manuscript status**
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

**Our Commitment**

| **Six weeks** |
|---|
| You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge. |

| **Four weeks** |
|---|
| After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript. |

**Mentored Review Articles (MRA)**
Our academic program “Mentored Review Article” (MRA) gives you a unique opportunity to publish papers under mentorship of international faculty. These articles are published free of charges.

**Most Favored Author program**
Join this program and publish any number of articles free of charge for one to five years.

**Favored Author program**
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

**Institutional Membership program**
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

**Our presence**
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

**Something more...**
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.